Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06616571 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints

StatusUnknown
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 27, 2024 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this real-world study is to compare the efficacy and safety of QL0605 administered 24 hours and 48 hours after chemotherapy in breast cancer patients.
Trial Details
NCT Number NCT06616571
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Chemotherapy-Induced Febrile Neutropenia
Enrollment 336 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov